Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

#1039

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF

Aim(s): To verify if IGF1R and EGFR could be involved in Sunitinib mechanism of action in BP-NET

Materials and methods: Human BP-NET cell lines and human BP primary cultures were treated with sunitinib and/or EGF, IGF1, or VEGF. Cell viability and caspase 3/7 activation were measured after 48 h of treatment. Receptor expression was detected by Western blot in cell lines and primary cultures. IGF1R and EGFR phosphorylation was analysed by alphascreen sure fire assay

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gagliano T

Authors: Gagliano T, Benfini K, Gentilin E, Falletta S, Di Pasquale C,

Keywords: RTK, BP-NET, IGF1R, EGFR,